Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma

Overview of attention for article published in Journal of Hematology & Oncology, April 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#42 of 1,275)
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

So far, Altmetric has seen 7 news stories from 7 outlets.

Kite, la compañía de terapia celular de Gilead Sciences, ha anunciado los datos de los análisis de seguimiento del estudio…

Redacción Kite ha anunciado los datos de los análisis de seguimiento de estudio pivotal ZUMA-2 con brexucabtagén autoleucel (Teca…

MADRID, 12 Dic. (EUROPA PRESS) - La compañía de terapia celular de Gilead Sciences, Kite, ha anunciado nuevos datos de los anális…

Kite, la compañía de terapia celular de Gilead Sciences, ha anunciado en la cita anual de la American Society of Hematology (ASH…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 3 additional news stories.